“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Click here for the full story

IMMX Insider Trading

Insider Ownership Percentage: 51.30%
Insider Buying (Last 12 Months): $5,200.00
Insider Selling (Last 12 Months): $550.00

Immix Biopharma Insider Trading History Chart

This chart shows the insider buying and selling history at Immix Biopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Immix Biopharma Share Price & Price History

Current Price: $3.14
Price Change: Price Increase of +0.52 (19.85%)
As of 02/3/2023 01:00 AM ET

This chart shows the closing price history over time for IMMX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Immix Biopharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/14/2022Ilya M RachmanCEOBuy5,200$1.00$5,200.00907,700View SEC Filing Icon  
7/14/2022Sean SennMajor ShareholderSell200$2.75$550.00899,800View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Immix Biopharma (NASDAQ:IMMX)

2.15% of Immix Biopharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at IMMX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Immix Biopharma Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/1/2023Bank of Montreal Can15,000$36K0.0%N/A0.108%Search for SEC Filing on Google Icon
11/15/2022Vanguard Group Inc.105,125$0.14M0.0%+106.5%0.755%Search for SEC Filing on Google Icon
11/14/2022Renaissance Technologies LLC27,050$37K0.0%N/A0.194%Search for SEC Filing on Google Icon
8/15/2022State Street Corp38,560$100K0.0%N/A0.278%Search for SEC Filing on Google Icon
5/17/2022Virtu Financial LLC23,515$57K0.0%N/A0.170%Search for SEC Filing on Google Icon
5/13/2022Renaissance Technologies LLC62,600$0.15M0.0%N/A0.452%Search for SEC Filing on Google Icon
5/13/2022XTX Topco Ltd12,992$31K0.0%N/A0.094%Search for SEC Filing on Google Icon
5/11/2022InterOcean Capital Group LLC15,900$38K0.0%N/A0.115%Search for SEC Filing on Google Icon
2/14/2022Altium Capital Management LP122,388$0.44M0.1%N/A1.616%Search for SEC Filing on Google Icon
2/14/2022Murchinson Ltd.695,600$2.48M0.2%N/A9.183%Search for SEC Filing on Google Icon
2/9/2022Context Capital Management LLC11,532$41K0.0%N/A0.152%Search for SEC Filing on Google Icon
2/2/2022PVG Asset Management Corp20,000$71K0.3%N/A0.264%Search for SEC Filing on Google Icon
2/1/2022Eidelman Virant Capital29,856$0.10M0.0%N/A0.394%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Immix Biopharma logo
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Read More on Immix Biopharma

Today's Range

Now: $3.14
Low: $2.53
High: $3.28

50 Day Range

MA: $2.01
Low: $1.05
High: $3.14

52 Week Range

Now: $3.14
Low: $0.68
High: $5.37

Volume

535,997 shs

Average Volume

224,566 shs

Market Capitalization

$43.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Immix Biopharma?

Immix Biopharma's top insider investors include:
  1. Ilya M Rachman (CEO)
  2. Sean Senn (Major Shareholder)
Learn More about top insider investors at Immix Biopharma.

Who are the major institutional investors of Immix Biopharma?

Immix Biopharma's top institutional shareholders include:
  1. Bank of Montreal Can — 0.11%
Learn More about top institutional investors of Immix Biopharma stock.

Which major investors are buying Immix Biopharma stock?

In the last quarter, IMMX stock was bought by institutional investors including:
  1. Bank of Montreal Can
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Click here for the full story